



Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		60726-AZ/JPW/GJG/DJK	Not yet known
		Applicants: Moses Rodriguez and Daren Ure	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		Filing Date herewith	Group Art Unit 1649

## U.S. PATENT DOCUMENTS

Examiner Initial	Exhibit No.	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
CYW		5 5 9 1 6 2 9	1/7/1997	Rodriguez, et al.			
		5 8 0 0 8 0 8	9/1/1998	Konfino, et al.			
		5 9 8 1 5 8 9	11/9/1999	Konfino, et al.			
		6 0 4 8 8 9 8	4/11/2000	Konfino, et al.			
		6 0 5 4 4 3 0	4/25/2000	Konfino, et al.			
CYW	1	20 02 01 82 2 1 0	12/5/2002	Rodriguez, et al.			

## FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
CYW	WO 00 0 5 2 5 0	2/3/2000					

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CYW	2	Allowed claims of U.S. Serial No. 09/885,227 (Rodriguez, et al.), U.S. Patent Publication No. 20020182210 A1, for the Examiner's convenience.
		Ben-Nun, A. et al. 1996. The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of Copolymer 1 on MOG-induced disease. J. Neurol. 243(Suppl 1): S14-S22.
		Fridkis-Hareli, et al., "Direct Binding of Myelin Basic Protein and Synthetic Copolymer 1 to Class II Major Histocompatibility Complex Molecules on Living Antigen-Presenting Cells - Specificity and Promiscuity", Proc. Natl. Acad. Sci. USA, 1994, 91: 4872-4876.
CYW		Lisak, R.P. et al. 1983. Effect of treatment with Copolymer 1 (Cop-1) on the in vivo and in vitro manifestations of Experimental Allergic Encephalomyelitis (EAE). J. Neurol. Sci. 62: 281-293.

EXAMINER	<i>Choy</i>	DATE CONSIDERED	01/20/06
----------	-------------	-----------------	----------

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60726-AA/ JPW/ GJG/DJK		Serial No. Not yet known	
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)					Applicants: Moses Rodriguez and Daren Ure			
					Filing Date herewith		Group Art Unit 1649	
<b>U.S. PATENT DOCUMENTS</b>								
Examiner Initial	Exhibit No.	Document Number				Date	Name	Class
<b>FOREIGN PATENT DOCUMENTS</b>								
		Document Number				Date	Country	Class
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>								
Cyl		Pavelko, K.D., B.G. van Engelen and M. Rodriguez. 1998. Acceleration in the rate of CNS remyelination in lysolecithin-induced demyelination. J. Neurosci. 18: 2498-2505.						
		Puri et al., "Modulation of the Immune Response in Multiple Sclerosis", J. Immunol., 1997, 158: 2471-2476.						
		Sela, M. et al. 1990. Suppressive activity of Cop-I in EAE and its relevance to multiple sclerosis. Bull. Inst. Pasteur. 88:303-314.						
		Teitelbaum, D., A. Meshorer, T. Hirshfeld, R. Arnon and M. Sela. 1971. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur. J. Immunol. 1: 242-248.						
		Teitelbaum, D., C. Webb, A. Meshorer, R. Arnon and M. Sela. 1973. Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen. Eur. J. Immunol. 3: 273-279.						
		Teitelbaum, D. et al. 1996. Copolymer I inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. J. Neuroimmunol. 64: 209-217.						
		Teitelbaum, D., R. Aharoni, M. Sela and R. Arnon. 1991. Cross-reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic Copolymer 1. Proc. Natl. Acad. Sci. USA 88:9528-9532.						
Cyl		Webb, C. et al. 1973. In vivo and in vitro immunological cross-reactions between basic encephalitogen and synthetic basic polypeptides capable of suppressing Experimental Allergic Encephalomyelitis, Eur. J. Immunol. 3: 279-286.						
EXAMINER <i>Changfeng Tang</i>		DATE CONSIDERED 1/20/06						
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								



Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office

Atty. Docket No. 60726-AZ U.S. Serial No. 10/776,442

INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)

Applicant: Moses Rodriguez and Daren Ure

Filing Date: February 10, 2004 Group Art Unit 1614-1649

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
CyW	US 3 8 4 9 5 5 0	11/19/74	Teitelbaum et al.			
CyW	US 3 9 9 1 2 1 0	11/09/76	Shea			
CyW	US 4 3 3 9 4 3 1	7/13/82	Gaffer			

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation	
					Yes	No
CyW WO 8 8 1 0 1 2 0	12/29/88	PCT				
CyW WO 9 2 0 2 5 4 3	2/20/92	PCT				
CyW WO 9 4 0 3 4 8 4	2/17/94	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


CyW	Abramsky, et al., "Effect of a Synthetic Polypeptide (COP-1) on Patients with Multiple Sclerosis and with Acute Disseminated Encephalomyelitis", <u>J. Neurol. Sci.</u> , 1977, 31, 433-438;
	Aharoni, et al., "T Suppressor Hybridomas and Interleukin-2-Dependent Lines Induced by Copolymer 1 or by Spinal Cord Homogenate Down-Regulate Experimental Allergic Encephalomyelitis", <u>Eur. J. Immunol.</u> , 1993, 23, 17-25;
	Aharoni, et al., "Studies on the Mechanism and Specificity of the Effect of the Synthetic Random Copolymer GLAT on Graft-versus-Host Disease", <u>Immunol. Letters</u> , 1997, 58, 79-87;
	Alvord, et al., "Myelin Basic Protein Treatment of Experimental Allergic Encephalomyelitis in Monkeys", <u>Ann. Neurol.</u> , 1979, 6, 469-473;
	Arnon, et al., "Suppression of Experimental Allergic Encephalomyelitis by a Synthetic Copolymer Immunological Cross Reactive with Basic Encephalitogen", <u>Israel J. Med. Sci.</u> , 1972, 8, 1759-17
	Arnon, et al., "Suppression of EAE in Baboons by a Synthetic Polymer of Amino Acids", <u>Neurol.</u> , 1978, 28, 336 (Abstract);
	Arnon, "A Synthetic Copolymer of Amino Acids in a Clinical Trial for MS Therapy" in <u>Progress in Multiple Sclerosis Research</u> (Bauer, Ritter, eds., Springer Verlag New York, 1980) 416-418;
	Arnon, et al., "Desensitization of Experimental Allergic Encephalomyelitis with Synthetic Peptide Analogues" in <u>The Suppression of Experimental Allergic Encephalomyelitis and Multiple Sclerosis</u> (Academic Press, New York, 1980) 105-107;
	Arnon, "Experimental Allergic Encephalomyelitis - Susceptibility and Suppression", <u>Immunological Rev.</u> , 1981, 55, 5-30;
CyW	Arnon, et al., "Suppression of Demyelinating Diseases by Synthetic Copolymers", in <u>A Multidisciplinary Approach to Myelin Disease</u> (G. Serlupi Crescenzi, ed., Plenum Publishing Corp., 1988) 243-250;

EXAMINER *Chang-Ha Song* DATE CONSIDERED 1/20/06

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 60726-AZ		U.S. Serial No. 10/776,442				
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Applicant: Moses Rodriguez and Daren Ure						
				Filing Date: February 10, 2004		Group Art Unit 1614 1649				
<b>U.S. PATENT DOCUMENTS</b>										
Examiner Initial		Document Number			Date	Name	Class	Subclass	Filing Date if Appropriate	
CyW		US 5 2 0 4 0 9 9	4/20/93	Barbier et al.						
CyW		US 5 5 5 4 3 7 2	9/10/96	Hunter et al.						
CyW		US 5 5 8 3 0 3 1	12/10/96	Stern						
<b>FOREIGN PATENT DOCUMENTS</b>										
		Document Number			Date	Country	Class	Subclass	Translation	
									Yes No	
CyW		WO 9 4 2 6 7 7 4	11/24/94	PCT						
CyW		WO 9 5 3 1 9 9 7	11/30/95	PCT						
CyW		WO 9 5 3 3 4 7 5	12/14/95	PCT						
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>										
CyW		Arnon, et al., "Suppression of Experimental Allergic Encephalomyelitis by Cop-1 - Relevance to Multiple Sclerosis", <u>Israel J. Med. Sci.</u> , 1989, 25, 686-689;								
		Arnon, et al., "On the Existence of Suppressor Cells", <u>Int. Arch. Allergy Immunol.</u> , 1993, 100, 2-7;								
		Arnon, et al., "Immunomodulation of Experimental Allergic Encephalomyelitis", <u>Israel J. Med. Sci.</u> , 1993, 29, 175-181;								
		Arnon, et al., "Immunospecific Drug Design - Prospects for Treatment of Autoimmune Disease", <u>Therapeutic Immunol.</u> , 1994, 1, 65-70;								
		Asakura and Rodriguez, "A Unique Population of Circulating Autoantibodies Promotes Central Nervous System Remyelination", <u>Multiple Sclerosis</u> , 1998, 4, 217-221;								
		Asakura, et al., "Targeting of IgMk Antibodies to Oligodendrocytes Promotes CNS Remyelination", <u>J. Neurosci.</u> , 1998, 18(19): 7700-7708;								
		Babu, et al., "Reevaluation of Response Patterns of Nonresponder Mice to GIPhe Polymers", <u>Immunogen.</u> , 1983, 18(1): 97-100 (Abstract);								
		Babu, et al., "Ir Gene Control of T and B Cell Responses to Determinants in (Glu Lys Ala) Terpolymer", <u>J. Immunogenet.</u> , 1984, 11(3-4): 251-254;								
		Bansil, et al., "Multiple Sclerosis: Pathogenesis and Treatment", <u>Seminars in Neurol.</u> , June 1994, 14(2), 146-153;								
		Baumhefner, et al., "Copolymer 1 as Therapy for Multiple Sclerosis: The Cons", <u>Neurol.</u> , 1988, 38(Suppl. 2), 69-71;								
		Baxevanis, et al., "Genetic Control of T-Cell Proliferative Responses to Poly (Glu <sup>40</sup> Ala <sup>60</sup> ) and Poly (Glu <sup>51</sup> Lys <sup>34</sup> Tyr <sup>15</sup> ): Subregion-Specific Inhibition of the Responses with Monoclonal Ia Antibodies", <u>Immunogenetics</u> , 1980, 11: 617-628;								
CyW		Bieber, et al., "Antibody-Mediated Remyelination: Relevance to Multiple Sclerosis", <u>Multiple Sclerosis</u> , 2000, 6: S1-S5;								
EXAMINER		Chang			DATE CONSIDERED			1/20/06		
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.										

<b>Form PTO-1449</b>		<b>U.S. Department of Commerce Patent and Trademark Office</b>		Atty. Docket No. 60726-AZ	U.S. Serial No. 10/776,442		
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)				Applicant: Moses Rodriguez and Daren Ure			
				Filing Date: February 10, 2004	Group Art Unit 1614 1649		
<b>U.S. PATENT DOCUMENTS</b>							
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
CyW	US	5 6 2 3 0 5 2	04/22/97	McLean et al			
CyW	US	5 6 2 7 2 0 6	05/06/97	Hupe et al			
CyW	US	5 6 6 8 1 1 7	09/16/97	Shapiro			
<b>FOREIGN PATENT DOCUMENTS</b>							
		Document Number	Date	Country	Class	Subclass	Translation
							Yes No
CyW	WO	9 5 2 6 9 8 0	10/12/95	PCT			
CyW	WO	9 5 3 1 9 9 0	11/30/95	PCT			
CyW	WO	9 8 3 0 2 2 7	07/16/98	PCT			
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
CyW		Bieber, et al., "Humoral Autoimmunity as a Mediator of CNS Repair", <u>Trends in Neurosci.</u> , 2001, 24(11): S39-S44;					
		Bornstein, et al., "Treatment of Multiple Sclerosis with a Synthetic Polypeptide: Preliminary Results", <u>Ann. Neurol.</u> , 1980, 8, 117 (Abstract);					
		Bornstein, et al., "Treatment of Multiple Sclerosis with a Synthetic Polypeptide: Preliminary Results", <u>Trans. Am. Neurol. Assoc.</u> , 1980, 105, 348-350;					
		Bornstein, et al., "Multiple Sclerosis: Trial of a Synthetic Polypeptide", <u>Ann. Neurol.</u> , 1982, 11, 317-319;					
		Bornstein, et al., "Clinical Trials of Copolymer 1 in Multiple Sclerosis", <u>Ann. N.Y. Acad. Sci. (USA)</u> , 1984, 366-372;					
		Bornstein, et al., "Clinical Trials of a Synthetic Polypeptide (Copolymer 1) for the Treatment of Multiple Sclerosis" in Gonsett et al., <u>Immunological and Clinical Aspects of Multiple Sclerosis</u> (MTP Press, The Hague, 1984) 144-150;					
		Bornstein, et al., "Multiple Sclerosis: Clinical Trials of a Synthetic Polypeptide, Copolymer 1", <u>Neurol.</u> , 1985, 35 (Suppl. 1), 103 (Abstract);					
		Bornstein, "Cop 1 May be Beneficial for Patients with Exacerbating-remitting Form of Multiple Sclerosis", <u>Adv. Ther. (USA)</u> , 1987, 4, 206 (Abstract);					
		Bornstein, et al., "A Pilot Trial of Cop 1 in Exacerbating-remitting Multiple Sclerosis", <u>New Eng. J. Med.</u> , 1987, 317(7), 408-414;					
		Bornstein, et al., "Clinical Experience with COP-1 in Multiple Sclerosis", <u>Neurol.</u> , 1988, 38(Suppl. 2), 66-69;					
CyW		Bornstein, et al., "Pilot Trial of COP-1 in Chronic Progressive Multiple Sclerosis: Preliminary Report", from <u>The International Multiple Sclerosis Conference: An Update on Multiple Sclerosis</u> , Roma (Italy), September 15-17, 1988, in <u>Elsevier Science Publisher</u> , 1989, 225-232;					
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>					
Chang-Yu Jung		1/20/06					
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60726-AZ		U.S. Serial No. 10/776,442						
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)					Applicant: Moses Rodriguez and Daren Ure								
					Filing Date: February 10, 2004		Group Art Unit 1614 1649						
<b>U.S. PATENT DOCUMENTS</b>													
Examiner Initial		Document Number			Date	Name	Class	Subclass	Filing Date if Appropriate				
CyW	US	5	7	1	9	2	6	9	02/17/98	Acton, III et al.			
CyW	US	5	7	3	4	0	2	3	03/31/98	Bishwajit et al.			
CyW	US	5	8	5	8	9	6	4	01/12/99	Aharoni, et al.			
<b>FOREIGN PATENT DOCUMENTS</b>													
		Document Number			Date	Country	Class	Subclass	Translation				
									Yes	No			
CyW	WO	0	0	0	5	2	4	9	02/03/00	PCT			
CyW	WO	0	0	1	8	7	9	4	04/06/00	PCT			
CyW	WO	0	0	2	0	0	1	0	04/13/00	PCT			
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>													
CyW		Bornstein, et al., "A Pilot Trial of Cop 1 in Exacerbating-remitting Multiple Sclerosis", <u>New Eng. J. Med.</u> , 1987, 317(7), 408-414;											
		Bornstein, et al., "Clinical Experience with COP-1 in Multiple Sclerosis", <u>Neurol.</u> , 1988, 38(Suppl. 2), 66-69;											
		Bornstein, et al., "Pilot Trial of COP-1 in Chronic Progressive Multiple Sclerosis: Preliminary Report", from <u>The International Multiple Sclerosis Conference: An Update on Multiple Sclerosis</u> , Roma (Italy), September 15-17, 1988, in <u>Elsevier Science Publisher</u> , 1989, 225-232;											
		Bornstein, et al., "Clinical Trials of Cop 1 in Multiple Sclerosis" in <u>Handbook of Multiple Sclerosis</u> (S.D. Cook Marcel Rekker, ed., 1990) 469-480;											
		Bornstein, et al., "A Placebo-controlled, Double-blind, Randomized Two-center, Pilot Trial of Cop 1 in Chronic Progressive Multiple Sclerosis", <u>Neurol.</u> , 1991, 41, 533-539;											
		Bornstein, et al., "Treatment of Multiple Sclerosis with Copolymer 1" in <u>Treatment of Multiple Sclerosis: Trial Design, Results and Future Perspectives</u> (Rudick R.A. & Goodkin D.E., eds., Springer Verlag, London, 1992) 173-198;											
		Brosnan, et al., "The Response of Normal Human Lymphocytes to Copolymer 1", <u>J. Neuropath. Exp. Neurol.</u> , 1983, 42, 356 (Abstract);											
		Brosnan, et al., "Copolymer 1: Effect on Normal Human Lymphocytes", <u>Ann. N.Y. Acad. Sci. (USA)</u> , 1984, 436, 498-499;											
		Brosnan, et al., "Immunogenic Potentials of Copolymer 1 in Normal Human Lymphocytes", <u>Neurol.</u> , 1985, 35, 1754-1759;											
CyW		Burns, et al., "Human Cellular Immune Response in Vitro to Copolymer 1 and Myelin Basic Protein (MBP)", <u>Neurol.</u> , 1985, 35 (Suppl. 1), 170 (Abstract);											
EXAMINER					DATE CONSIDERED 1/20/06								
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60726-AZ		U.S. Serial No. 10776,442	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicant: Moses Rodriguez and Daren Ure			
					Filing Date: February 10, 2004		Group Art Unit 1614-1649	
<b>U.S. PATENT DOCUMENTS</b>								
Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate		
CyW	US 5 8 8 6 1 5 6	03/23/99	McLean et al.					
CyW	US 5 9 5 8 9 7 2	09/28/99	Hupe, et al.					
CyW	US 6 2 1 4 7 9 1	04/10/01	Arnon, et al.					
<b>FOREIGN PATENT DOCUMENTS</b>								
	Document Number	Date	Country	Class	Subclass	Translation		
						Yes	No	
CyW	WO 0 0 2 7 4 1 7	05/18/00	PCT					
CyW	WO 0 1 8 5 7 9 7	11/15/01	PCT					
CyW	WO 0 1 5 2 8 7 8	07/26/01	PCT					
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>								
CyW	Burns, et al., "Human Cellular Immune Response to Copolymer 1 and Myelin Basic Protein", <u>Neurol.</u> , 1986, <u>36</u> , 92-94;							
	Burns, et al., "Failure of Copolymer 1 to Inhibit the Human T-cell Response to Myelin Basic Protein", <u>Neurol.</u> , 1991, <u>41</u> , 1317-1319;							
	Carter, et al., "Newer Drug Therapies for Multiple Sclerosis", <u>Drug Therapy</u> , 1990, 31-32, 37-39, 42-43;							
	Clinical Trial Protocol No. 9001, Teva Pharmaceutical Industries, Ltd., first patient enrolled October 23, 1991;							
	Clinical Trial Protocol No. 9002, Lemmon Co. and Teva Pharmaceutical Industries, Ltd., first patient enrolled June 17, 1993;							
	Cohen, "Fundamental Immunology", <u>Systemic Autoimmunity</u> , 4 <sup>th</sup> Ed., 1999, 1083;							
	Cotton, "Options for Multiple Sclerosis Therapy", <u>J.A.M.A. Medical News &amp; Perspectives</u> , 1994, <u>272</u> (18), 1393;							
	De Kruffy, et al., "Analysis of T Cell Responses to Poly-L (GluLys) at the Clonal Level. I. Presence of Responsive Clones in Nonresponder Mice", <u>Eur. J. Immunol.</u> , 1987, 17 (8): 1115-1120 (Abstract);							
	Deeb, et al., "Comparision of Freund's and Ribi Adjuvants for Inducing Antibodies to the Synthetic Antigen (TG)-AL in Rabbits", <u>J. Immunol. Methods</u> , 1992, 152(1): 105-113 (Abstract);							
	Dorling, et al., "Prospects for Xenografting", <u>Curr. Opinions Immunol.</u> , 1994, <u>6</u> , 765-769;							
	Durelli, "Immunotherapeutics of Multiple Sclerosis", <u>Istituto di Clinica delle Malattie del Sistema Nervoso Universita di Torino</u> , 467-475;							
CyW	Falo et al., "Analysis of Antigen Presentation by Metabolically Inactive Accessory Cells and Their Isolated Membranes", <u>Proc. Natl. Acad. Sci. USA</u> , 1985, 82(19): 6647-6651 (Abstract);							
EXAMINER		DATE CONSIDERED						
Changshu Wang		1/20/06						
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>								



Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60726-AZ		U.S. Serial No. 10/776,442						
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicant: Moses Rodriguez and Daren Ure								
					Filing Date: February 10, 2004		Group Art Unit 1614-1649						
<b>U.S. PATENT DOCUMENTS</b>													
Examiner Initial	US	Document Number						Date	Name	Class	Subclass	Filing Date if Appropriate	
CyW	US	6	3	4	2	4	7	6	01/29/02	Konfino et al.			
CyW	US	6	3	6	2	1	6	1	03/26/02	Konfino et al.			
CyW	US-2001	00	5	5	5	6	8	A1	12/27/01	Gilbert et al.			
<b>FOREIGN PATENT DOCUMENTS</b>													
		Document Number						Date	Country	Class	Subclass	Translation Yes      No	
CyW	WO	0	1	9	3	8	9	3	12/13/01	PCT			
CyW	WO	0	1	6	0	3	9	2	08/23/01	PCT			
CyW	WO	0	1	9	3	8	2	8	12/13/01	PCT			
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>													
CyW		Ferrara, et al., "Graft-Versus-Host Disease", <u>New Eng. J. Med.</u> , 1991, 324, 667-674;											
		Francis, "The Current Therapy of Multiple Sclerosis", <u>J. Clin. Pharmacy and Therapeutics</u> , 1993, 18, 77-84;											
		Fridkis-Hareli, et al., "Copolymer 1 Displaces MBP, PLP and MOG, but Can Not be Displaced by these Antigens from the MHC Class II Binding Site", <u>Department of Chemical Immunology, The Weizmann Institute of Science</u> , 1994;											
		Fridkis-Hareli, et al., "Synthetic Copolymer 1 and Myelin Basic Protein do not Require Processing Prior to Binding to Class II Major Histocompatibility Complex Molecules on Living Antigen Presenting Cells", <u>Department of Chemical Immunology, The Weizmann Institute of Science, Rehovot, Israel</u> , 1994;											
		Fridkis-Hareli, et al., "Specific and Promiscuous Binding of Synthetic Copolymer 1 to Class II Major Histocompatibility Complex Molecules on Living Antigen Presenting Cells", <u>Israeli Biochem. Soc.</u> , 1994, 21-22 (Abstract);											
		Fridkis-Hareli, et al., "Synthetic Copolymer 1 and Myelin Basic Protein Do Not Undergo Processing Prior to the Binding to Class II Major Histocompatibility Complex Molecules on Antigen Presenting Cells", <u>Israeli Immunol. Soc.</u> , May 3-4, 1994 (Abstract);											
		Fridkis-Hareli, et al., "Synthetic Copolymer 1 Inhibits the Binding of MBP, PLP and MOG Peptides to Class II Major Histocompatibility Complex Molecules on Antigen-Presenting Cells", <u>J. Neurochem.</u> , 1994, 63(Suppl. I), 561;											
		Fridkis-Hareli, et al., "Synthetic Copolymer 1 Inhibits the Binding of MBP, PLP and MOG Peptides to Class II Major Histocompatibility Complex Molecules on Antigen Presenting Cells" in <u>Neurochem Mtg.</u> , August 14-19, 1994;											
		Fridkis-Hareli, et al., "Synthetic Copolymer 1 and Myelin Basic Protein Do Not Require Processing Prior to Binding to Class II Major Histocompatibility Complex Molecules on Living Antigen-Presenting Cells", <u>Cell. Immunol.</u> , 1995, 163, 229-236;											
CyW		Fridkis-Hareli, et al., "Promiscuous Binding of Synthetic Copolymer 1 to Purified HLA-DR Molecules", <u>J. Immunol.</u> , 1998, 160, 4386-4397;											
EXAMINER		<div style="display: flex; justify-content: space-between;"> <span><i>Cheng-Yu Wang</i></span> <span>DATE CONSIDERED 12/06/06</span> </div>											
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>													

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60726-AZ		U.S. Serial No. 10/776,442						
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicant: Moses Rodriguez and Daren Ure								
					Filing Date: February 10, 2004		Group Art Unit 1614-1649						
<b>U.S. PATENT DOCUMENTS</b>													
Examiner Initial		Document Number				Date	Name	Class	Subclass	Filing Date if Appropriate			
CYW	US-2002	00	3	7	8	4	8	A1	03/28/02	Eisenbach-Schwartz et al.			
CYW	US-2002	00	3	7	8	4	8	A1	03/28/02	Eisenbach-Schwartz et al.			
CYW	US-2003	00	0	4	0	9	9	A1	01/02.03	Eisenbach-Schwartz et al.			
<b>FOREIGN PATENT DOCUMENTS</b>													
		Document Number				Date	Country	Class	Subclass	Translation			
										Yes	No		
CYW	WO	0	1	9	7	8	4	6	12/27/01	PCT			
CYW	EP	0	3	5	9	7	8	3	08/22/90	Europe			
CYW	EP	0	3	8	3	6	2	0	11/29/95	Europe			
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>													
CYW		Fridkis-Hareli, et al., "Synthetic Amino Acid Copolymers that Bind to HLA-DR Proteins and Inhibit Type II Collagen-reactive T Cell Clones", <u>Proc. Natl. Acad. Sci.</u> , October 1998, <b>95</b> , 12528-12531;											
		Fridkis-Hareli, et al., "Binding of Random Copolymers of Three Amino Acids to Class II MHC Molecules", <u>Intl. Immunol.</u> , 1999, <b>11</b> (5): 635-641;											
		Fridkis-Hareli, et al., "Synthetic Peptides that Inhibit Binding of the Collagen Type II 261-273 Epitope to Rheumatoid Arthritis-Associated HLA-DR1 and DR4 Molecules and Collagen-Specific T-cell Responses", Database HCAPLUS on STN, Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark, HCAPLUS AN: 2000:455053, Human Immunology, 2000, <b>61</b> (7), 640-650 (Abstract);											
		Grgacic, et al., "Cell-mediated Immune Response to Copolymer 1 in Multiple Sclerosis Measured by the Macrophage Procoagulant Activity Assay", <u>Int. Immunol.</u> , 1990, <b>2</b> (8), 713-718;											
		Harrison and Hafler, "Antigen-Specific Therapy for Autoimmune Disease", <u>Current Opin. Immunol.</u> , 2000, <b>12</b> (6): 704-711;											
		Henry, Celia M., "Special Delivery", <u>Chem. and Eng. News</u> , Sept. 18, 2000, 49-54;											
		Herzenberger, et al., "Lack of Immune Response Gene Control for Induction of Epitope-specific Suppression by TGAL Antigen", <u>Nature</u> , 1982, <b>295</b> : 329-331 (Abstract);											
		Jacobs, et al., "Advances in Specific Therapy for Multiple Sclerosis", <u>Neurol.</u> , 1994, <b>7</b> , 250-254;											
		Johnson, "Clinical Studies in Copolymer 1 Therapy for Exacerbating-relapsing Multiple Sclerosis", in <u>Congress for Advances in the Understanding and Treatment of Multiple Sclerosis</u> , Boston (USA), Oct. 28-29, 1992;											
CYW		Johnson, "Experimental Therapy of Relapsing-Remitting Multiple Sclerosis with Copolymer-1", <u>Ann. Neurol.</u> , 1994, <b>36</b> (Suppl.), 115-117;											
EXAMINER		<i>Chang-Yu Tang</i>				DATE CONSIDERED				1/20/06			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60726-AZ		U.S. Serial No. 10/776,442						
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicant: Moses Rodriguez and Daren Ure								
					Filing Date: February 10, 2004		Group Art Unit <del>1614</del> 1649						
<b>U.S. PATENT DOCUMENTS</b>													
Examiner Initial	US	Document Number						Date	Name	Class	Subclass	Filing Date if Appropriate	
CYW	US	09	3	5	9	0	9	9	07/12/99	Strominger et al.			
CYW	US	09	4	0	5	7	4	3	09/24/99	Gad et al.			
CYW	US	09	4	8	7	7	9	3	01/20/00	Eisenbach-Schwartz, et al.			
<b>FOREIGN PATENT DOCUMENTS</b>													
		Document Number						Date	Country	Class	Subclass	Translation	
												Yes	No
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>													
CYW		Johnson, Management of Relapsing/Remitting Multiple Sclerosis with Copolymer 1 (Copaxone)", <u>Chemical Abstracts</u> , 1996, <u>125</u> , 291993b;											
		Ju, et al., "Idiotypic Analysis of Antibodies Against the Terpolymer L-glutamic Acid 60-L-alanine30-L-tyrosine10 (GAT). IV. Induction of CGAT Idiotypic Following Immunization with Various Synthetic Polymers Containing Glutamic Acid and Tyrosine", <u>Eur. J. Immunol.</u> , 1979, 9(7): 553-560 (Abstract);											
		Kay, et al., "The Mechanism of Action of FK 506", <u>Transplantation Proceedings</u> , 1990, 22(1, Suppl. 1), 96-99;											
		Keith, et al., "The Effect of COP 1, a Synthetic Polypeptide, on Chronic Relapsing Experimental Allergic Encephalomyelitis in Guinea Pigs" <u>J. Neurol. Sci.</u> , 1979, 42, 267-274;											
		Keleman, et al., "Graft-versus-Host Disease in Bone Marrow Transplantation: Experimental, Laboratory, and Clinical Contributions of the Last Few Years", <u>Int. Arch. Allergy Immunol.</u> , 1993, 102, 309-320;											
		Kepsutlu, et al., "Evaluation of Chitosan Used as an Excipient in Tablet Formulations", Database HCAPLUS on STN, Department of Pharmaceutical Technology, Gulhane Military Medical Academy, Ankara, 06018, Turkey, HCAPLUS AN: 1999: 590411, Acta. Pol. Pharm. 1999, 56(3), 227-235 (Abstract);											
		Kott, et al., "COP-1 Increases Suppressor Cells Number in Multiple Sclerosis", <u>Israel Neurological Assoc.</u> , December 19-20, 1994, Herzliya (Israel), 17;											
		Kropshofer, et al., "Self-Peptides from Four HLA-DR Alleles Share Hydrophobic Anchor Residues Near the NH <sub>2</sub> -Terminal Including Proline as a Stop Signal for Trimming", <u>J. Immunol.</u> , 1993, 151: 4732-4742;											
		Lai, et al., "Complementation of Class II a Alleles in the Immune Response to (Glulystyr) Polymers", <u>Exp. Clin. Immunogenet.</u> , 1986, 3(1): 38-48 (Abstract);											
CYW		Lai, et al., "Monoclonal T Cell Responses to Two Epitopes on a Single Immunogen Controlled by Two Distinct Genes", <u>J. Immunol.</u> , 1986, 136(10): 3799-3804 (Abstract);											
EXAMINER		Chang-Yu Song						DATE CONSIDERED		1/20/06			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60726-AZ		U.S. Serial No. 10/776,442						
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)					Applicant: Moses Rodriguez and Daren Ure								
					Filing Date: February 10, 2004		Group Art Unit 1614-1649						
<b>U.S. PATENT DOCUMENTS</b>													
Examiner Initial	US	Document Number			Date	Name	Class	Subclass	Filing Date if Appropriate				
CyW	US	09	6	2	0	2	1	6	07/20/00	Eisenbach-Schwartz, et al.			
CyW	US	09	7	6	5	3	0	1	01/22/01	Eisenbach-Schwartz, et al.			
CyW	US	09	7	6	5	6	4	4	1/22/01	Eisenbach-Schwartz, et al.			
<b>FOREIGN PATENT DOCUMENTS</b>													
		Document Number			Date	Country	Class	Subclass	Translation				
									Yes	No			
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>													
CyW		Lando, et al., "Experimental Allergic Encephalomyelitis in Mice - Suppression and Prevention with COP-1", <u>Israel J. Med. Sci.</u> , 1979, 15, 868-869 (Abstract);											
		Lando, et al., "Effect of Cyclophosphamide on Suppressor Cell Activity in Mice Unresponsive to EAE", <u>J. Immunol.</u> , 1979, 123, 2156-2160 (Abstract);											
		Lee, et al., "Peptide and Protein Drug Delivery" in <u>Advances in Parenteral Sciences</u> (Vincent H.L. Lee, ed., Marcel Dekker, Inc., 1990) 691-695;											
		Li et al., "Glatiramer Acetate Blocks the Activation of THP-1 Cells by Interferon-γ", <u>Eur. J. Pharmacol.</u> , 1998, 342: 303-310;											
		Lisak, et al., "Effect of Treatment with Copolymer 1 (Cop-1) on the in Vivo and in Vitro Manifestations of Experimental Allergic Encephalomyelitis (EAE)", <u>J. Neurol. Sci.</u> , 1983, 62, 281-293;											
		Matsunaga, et al., "Complementation of Class II A Alleles in the Immune Response to (Glu-Lys-Tyr) Polymers", <u>Yokohama Med. Bull.</u> , 1988, 39(1-2): 9-19 (Abstract);											
		Maurer, et al., "Interpretations of Immune Responses of Mice to Poly(Glu60Lys40), its Modified Derivatives, and the Terpolymers Poly (Glu55Lys37Leu8) and Poly (Glu56Lys37Ser7)", <u>Clin. Immunol. Immunopathol.</u> , 1980, 15(3): 344-356 (Abstract);											
		McDermott, et al., "Antigen-induced Suppression of Experimental Allergic Neuritis in the Guinea Pig", <u>J. Neurol. Sci.</u> , 1980, 46, 137-143;											
		McGavern, et al., "Do Antibodies Stimulate Myelin Repair in Multiple Sclerosis", <u>The Neuroscientist</u> , 1999, 5(1): 19-28;											
		Meiner, "COP-1 Multicenter Clinical Trial in Exacerbating-remitting Multiple Sclerosis: One Year Follow-up", <u>J. Neurol.</u> , 1991(Suppl. 1) (Abstract);											
		Meiner, et al., "The Israeli COP-1 Multicenter Clinical Trial in Exacerbating-remitting Multiple Sclerosis - Two-year Follow-up", in <u>9<sup>th</sup> Congress of the European Committee for Treatment and Research in Multiple Sclerosis</u> , Florence (Italy), October-November, 1993, 48 (Abstract);											
CyW		Mengle-Gaw, "The Major Histocompatibility Complex (MHC)", in <u>Encycl. Molecular Bio.</u> (Oxford Blackwell Science Ltd, 1994) 602-606;											
EXAMINER		Chang			DATE CONSIDERED		01/20/06						
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60726-AZ		U.S. Serial No. 10/776,442					
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicant: Moses Rodriguez and Daren Ure							
					Filing Date: February 10, 2004		Group Art Unit 1614-1649					
<b>U.S. PATENT DOCUMENTS</b>												
Examiner Initial	US	Document Number					Date	Name	Class	Subclass	Filing Date if Appropriate	
Cyw	US	09	7	6	8	8	7	2	01/23/01	Aharoni et al.		
Cyw	US	09	8	1	6	9	8	9	03/23/01	Gad et al.		
Cyw	US	09	8	7	5	4	2	9	06/05/01	Yong et al.		
<b>FOREIGN PATENT DOCUMENTS</b>												
		Document Number					Date	Country	Class	Subclass	Translation	
											Yes	No
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>												
Cyw		Milo, et al., "Inhibition of Myelin Basic Protein-specific Human T-cell Lines by COP-1", <u>Israel J. Med. Sci.</u> , 1992, 28, 486 (Abstract);										
		Milo, et al., "Copolymer-1 (COP-1) Regulates Class II MHC Expression and Cytokine Synthesis in the THP-1 Monocyte-Macrophage Cell Line" in <u>The IBC Conference on Multiple Sclerosis</u> , San Diego (USA), December 10, 1993 (Abstract);										
		Milo, et al., "Additive Effect of Copolymer-1 and Interferon- $\beta$ on the Immune Response to Myelin Basic Protein", <u>Assaf Harofeh Medical Center, Sackler School of Medicine, Tel-Aviv University of Maryland School of Medicine</u> , 1994, 22;										
		Milo, et al., "Copolymer-1 and Interferon- $\beta$ Additively Suppress the Immune Response to Myelin Basic Protein by Inhibiting Antigen Presentation", <u>J. Neuroimmunol.</u> , 1994, 54, 183 (Abstract);										
		Milo, et al., "Additive Effects of COP-1 and IFN-Beta on Immune Responses to Myelin Basic Protein", <u>Neurol.</u> , 1994, 44(Suppl. 2), A212;										
		Milo, et al., "Additive Effects of Copolymer-1 and Interferon $\beta$ -1b on the Immune Response to Myelin Basic Protein", <u>J. Neuroimmunol.</u> , 1995, 61, 185-193;										
		Milo, et al., "Additive Effects of COP-1 and IFN-Beta on Immune Responses to Myelin Basic Protein", <u>Neurol.</u> , 1994, 44(Suppl. 2), A212;										
		Myers, et al., "The Peculiar Difficulties of Therapeutic Trials for Multiple Sclerosis", <u>Neurologic Clinics</u> , 1990, 8(1), 119-141;										
		Nightingale, et al., "Access to Investigational Drugs for Treatment Purposes", <u>Am. Family Physician</u> , 1994, 50(4), 845-847;										
		O'Connor, et al., "Powders" in <u>The Science and Practice of Pharmacy</u> , Remington, 1995, 2, 1598-1614 Pender et al. <u>Int. Med. Journal</u> , 2002, 32: 554-563;										
Cyw		Porter, "Coating of Pharmaceutical Dosage Forms," in <u>The Science and Practice of Pharmacy</u> , Remington, 1995, 2, 1650-1659										
EXAMINER		Chang					DATE CONSIDERED		1/20/06			
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>												

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60726-AZ		U.S. Serial No. 10/776,442	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicant: Moses Rodriguez and Daren Ure			
					Filing Date: February 10, 2004		Group Art Unit 1614 1649	
<b>U.S. PATENT DOCUMENTS</b>								
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
<b>FOREIGN PATENT DOCUMENTS</b>								
		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>								
Cyn		Prat, et al., "Lymphocyte Migration and Multiple Sclerosis: Relation with Disease Course and Therapy," <u>Ann. Neurol.</u> , 1999, 46: 253-256;						
		Racke, et al., "Copolymer-1-induced Inhibition of Antigen-specific T Cell Activation: Interference with Antigen Presentation", <u>J. Neuroimmunol.</u> , 1992, 37, 75-84;						
		Reilly, Jr., W.J., "Pharmaceutical Necessities" in <u>The Science and Practice of Pharmacy</u> , Remington, 1995, 2, 1380-1416;						
		Rodriguez, <u>Neurological Therapeutics</u> , 1998, 15(3): 245-250;						
		Rolak, "Copolymer-I Therapy for Multiple Sclerosis", <u>Clin. Neuropharmacology</u> , 1987, 10(5), 389-396;						
		Schlegel, et al., "Prevention of Graft-Versus-Host Disease by Peptides Binding to Class II Major Histocompatibility Complex Molecules", <u>Blood</u> , 1994, 84(8), 2802-2810;						
		Schlegel, et al., "Inhibition of Allorecognition and Prevention of Graft-vs-host Disease (GVHD) by GLAT, a Synthetic Polymer with Promiscuous Binding to Murine and Human MHC Class II Molecules", in <u>Am. Soc. Hematology, 37<sup>th</sup> Annual Meeting</u> , Seattle, WA (USA), December 1-5, 1995, 224a (Abstract);						
		Schwartz, et al., "Gene Complementation in the T Lymphocyte Proliferative Response to Poly (Glu57Lys38Tyr5): Evidence for Effects of Polymer Handling and Gene Dosage", <u>J. Immunol.</u> , 1979, 123(1): 272-278 (Abstract);						
		Sela, et al., "Experimental Allergic Encephalomyelitis" in <u>Menarini Series on Immunopathology, vol. 1, First Symposium of Organ Specific Autoimmunity</u> , Cremona, Italy, June, 1977, (Miescher P.A. ed., Schwabe Co., Basel, 1978), 9-21;						
Cyn		Sela, "Polymeric Drugs as Immunomodulatory Vaccines Against Multiple Sclerosis", <u>Makromol. Chem. Macromol. Symp.</u> , 1993, 70/71, 147-155;						
EXAMINER		DATE CONSIDERED						
Chrym		12/0/06						
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant</p>								

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60726-AZ		U.S. Serial No. 10/776,442	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicant: Moses Rodriguez and Daren Ure			
					Filing Date: February 10, 2004		Group Art Unit 1614 1649	
<b>U.S. PATENT DOCUMENTS</b>								
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
<b>FOREIGN PATENT DOCUMENTS</b>								
		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>								
C/W		Starzl, Transplantation Proceedings, 1990, 22 (1, Suppl. 1), 5;						
		Sykes, "Immunobiology of Transplantation", <u>Faseb J.</u> , 1996, 10, 721-730;						
		Tarcic, et al., "Copolymer 1 (Copaxone) from an Idea to a Drug for Treatment of Multiple Sclerosis" Database HCAPLUS on STN, Israel: AN 1997:333270. Kim, Handasa Kim, 1997, 281(14), 16-18 (Abstract);						
		Teitelbaum, et al., "Suppression of Experimental Allergic Encephalomyelitis by a Synthetic Polypeptide", <u>Israel J. Med. Sci.</u> , 1971, 7, 630-631 (Abstract);						
		Teitelbaum, et al., "Protection Against Experimental Allergic Encephalomyelitis", <u>Nature</u> , 1972, 240, 564-566;						
		Teitelbaum, et al., "Suppression of Experimental Allergic Encephalomyelitis in Rhesus Monkeys by a Synthetic Basic Copolymer", <u>Clin. Immunol. Immunopath.</u> , 1974, 3, 256-262;						
		Teitelbaum, et al., "Dose-response Studies on Experimental Allergic Encephalomyelitis Suppression by COP-1", <u>Israel J. Med. Sci.</u> , 1974, 10(9), 1172-1173;						
		Teitelbaum, et al., "Suppression of Experimental Allergic Encephalomyelitis in Baboons by Cop 1", <u>Israel J. Med. Sci.</u> , 1977, 13, 1038 (Abstract);						
		Teitelbaum, et al., "Blocking of Sensitization to Encephalitogenic Basic Protein in Vitro by Synthetic Basic Copolymer (COP 1)" in <u>Cell Biology and Immunology of Leukocyte Function</u> (Academic Press, New York, 1979) 681-685;						
		Teitelbaum, "Suppression of Experimental Allergic Encephalomyelitis with a Synthetic Copolymer - Relevance to Multiple Sclerosis", in <u>Humoral Immunity in Neurological Diseases</u> (Karcher D., Lowenthal A. & Strosberg A.D., eds., Plenum Publishing Corp., 1979) 609-613;						
		Teitelbaum, et al., "Monoclonal Antibodies to Myelin Basic Protein Cross React with Synthetic EAE-suppressive Copolymer, COP 1" in <u>Proc. 7<sup>th</sup> Eur. Immunol. Mtg.</u> , Jerusalem, September 8-13, 1985 (Abstract);						
C/W		Teitelbaum, et al., "Specific Inhibition of the T-cell Response to Myelin Basic Protein by the Synthetic Copolymer Cop 1", <u>Proc. Natl. Acad. Sci. USA</u> , 1988, 85, 9724-9728;						
EXAMINER <i>Chang W. Song</i>		DATE CONSIDERED 1/20/06						
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant</p>								

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60726-AZ		U.S. Serial No. 10/776,442	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicant: Moses Rodriguez and Daren Ure			
					Filing Date: February 10, 2004		Group Art Unit <del>1614</del> 1649	
<b>U.S. PATENT DOCUMENTS</b>								
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
<b>FOREIGN PATENT DOCUMENTS</b>								
		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>								
Cyr		Teitelbaum, et al., "Clinical Trial of Copolymer 1 in Multiple Sclerosis" <u>J. Israel Med. Assoc.</u> , 1989, CXVI(9), 453-456;						
		Teitelbaum, et al., "Synthetic Copolymer 1 Inhibits Human T-cell Lines Specific for Myelin Basic Protein", <u>Proc. Natl. Acad. Sci. (USA)</u> , 1992, 89, 137-141;						
		Teitelbaum, et al., "Immunological Parameters in a Multicenter Clinical Trial of COP1 in Multiple Sclerosis (MS): A 2-year Follow-up", <u>Neurol.</u> , 1994, 44(Suppl. 2), A358;						
		Teitelbaum, et al., "Copolymer 1 from the Laboratory to FDA", <u>Israel J. Med. Sci.</u> , 1997, 33, 280-284;						
Cyr		The COP-1 Multicenter Clinical and Research Group Study, "COP-1 Multicenter Trial in Relapsing Remitting Multiple Sclerosis: 3 Year Follow Up", <u>Abstracts of Symposia and Free Communication</u> , Barcelona (Spain), June 25-29, 1994, 241 (Suppl. 1), 6;						
-		Thompson, "MCQ Tutor: Medical Immunology Multiple Choice Questions", <u>Immunol. Today</u> , 1985, 6(4), 141;						
		Tisch, et al., "Antigen-specific immunotherapy: Is it a Real Possibility to Combat T-Cell-Mediated autoimmunity?" <u>Proc. Natl. Acad. Sci. U.S.A.</u> , 1994, 91, 437-438;						
		Trannoy, et al., "Epitope-specific Regulation of the T Cell Repertoire: Carrier Recognition in Association with I-E or I-A Does Not Influence the Restriction of Hapten-Specific T Cells", <u>Eur. J. Immunol.</u> , 1985, 15(12): 1215-1221 (Abstract);						
		Van den Bogaerde, et al., "Induction of Long-Term Survival of Hamster Heart Xenografts in Rats", <u>Transplantation</u> , 1991, 52, 15-20;						
		Van Noort, et al., <u>International Review of Cytology</u> , 1995, 178: 127-205;						
		Warrington, et al., "Human Monoclonal Antibodies Reactive to Oligodendrocytes Promote Remyelination in a Model of Multiple Sclerosis", <u>Neurobiology</u> , 2000, 97(12): 6820-6825;						
		Warrington, et al., "Immunoglobulin-Mediated CNS Repair", <u>J. Allergy Clin. Immunol.</u> , 2001, S121-S125;						
Cyr		Webb, et al., "Further Studies on the Suppression of Experimental Allergic Encephalomyelitis by Synthetic Copolymer", <u>Israel J. Med. Sci.</u> , 1972, 8, 656-657.						
EXAMINER		DATE CONSIDERED						
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant</p>								



Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60726-AZ		U.S. Serial No. 10/776,442	
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)					Applicant: Moses Rodriguez and Daren Ure			
					Filing Date: February 10, 2004		Group Art Unit 1614 1649	
<b>U.S. PATENT DOCUMENTS</b>								
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
<b>FOREIGN PATENT DOCUMENTS</b>								
		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>								
C/W		Webb, et al., "Molecular Requirements Involved in Suppression of EAE by Synthetic Basic Copolymers of Amino Acids", <u>Immunochem.</u> , 1976, 13, 333-337;						
		Webster's II New Riverside University Dictionary, The Riverside Publishing Company, 1984, 933;						
		Weinshenker, et al., "Natural History and Treatment of Multiple Sclerosis", <u>Current Opinion in Neurol. and Neurosurgery</u> , 1992, 5, 203-211;						
		Wender, "Copolymer 1 (COP-1) in the Treatment of Multiple Sclerosis (letter)" <u>Neur. Neurochir. Pol.</u> , 1990, 24, 113;						
		Winer, "COP 1 Therapy for Multiple Sclerosis", <u>New Eng. J. Med.</u> , 1987, 317(7), 442-444;						
		Zisman, et al., "Direct Binding of a Synthetic Multichain Polypeptide to Class II Major Histocompatibility Complex Molecules on Antigen-presenting Cells and Stimulation of a Specific T-cell Line Require Processing of the Polypeptide", <u>Proc. Natl. Acad. Sci. USA</u> , 1991, 88(21): 9732-9742 (Abstract);						
C/W		Zisman, et al., "Dichotomy Between the T and the B Cell Epitopes of the Synthetic Polypeptide (T,G)-A-L", <u>Eur. J. Immunol.</u> , 1994, 24(10): 2497-2505 (Abstract);						
EXAMINER		DATE CONSIDERED						
Chang in Sef		1/20/06						
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant								

